Insulin Prices

RFK Jr.’s FDA Pick: Cooking Classes Over Insulin for Diabetics

FDA Commissioner Marty Makary controversially suggested that cooking classes might be a more effective diabetes treatment than insulin alone, despite overwhelming scientific evidence supporting insulin’s safety and efficacy. This statement promotes a report from the Trump administration’s “Make America Healthy Again” commission, which advocates for a proactive healthcare system. However, the commission, led by Robert F. Kennedy Jr., has faced criticism for promoting unsubstantiated claims regarding vaccines, fluoride, and food dyes. Makary’s remarks thus align with a broader initiative criticized for prioritizing unproven approaches over established medical consensus.

Read More

Novo Nordisk Slashes Insulin Prices by Over 70%

Novo Nordisk’s recent announcement to slash US list prices of two insulin products by more than 70% is undeniably a significant event. This dramatic price reduction, while seemingly a benevolent act, is a complex issue with multiple contributing factors beyond simple corporate altruism.

The timing of this price cut is intriguing, coinciding with the Biden administration’s negotiations with pharmaceutical companies to lower Medicare drug prices. While the full effects of these negotiations won’t be felt until 2026, Novo Nordisk’s proactive move suggests a response to the broader pressure for affordability in the insulin market. It’s tempting to see this as a direct result of political pressure, and perhaps it partially is, but it’s likely more nuanced than that.… Continue reading